Monopar Therapeutics Stock Performance
| MNPR Stock | USD 22.53 1.83 8.84% |
Monopar Therapeutics holds a performance score of 11 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -4.46, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Monopar Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Monopar Therapeutics is expected to outperform it. Use Monopar Therapeutics value at risk, as well as the relationship between the kurtosis and price action indicator , to analyze future returns on Monopar Therapeutics.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Monopar Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Monopar Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 8.84 | Five Day Return 10.99 | Year To Date Return 1.1 K | Ten Year Return (83.00) | All Time Return (83.00) |
Last Split Factor 1:5 | Last Split Date 2024-08-13 |
1 | Disposition of 13841 shares by Cittadine Andrew of Monopar Therapeutics subject to Rule 16b-3 | 09/24/2024 |
2 | Disposition of 1791 shares by Cittadine Andrew of Monopar Therapeutics subject to Rule 16b-3 | 09/30/2024 |
3 | Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers | 10/15/2024 |
4 | Monopar Therapeutics Shares Surge on Partnership with Alexion | 10/24/2024 |
5 | Whats Going On With Monopar Therapeutics Shares Friday | 10/25/2024 |
6 | Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock | 10/28/2024 |
7 | Will Monopar Therapeutics continue to fall in November | 10/29/2024 |
8 | Insider Purchase CFO Karthik Radhakrishnan Acquires Shares of Monopar Therapeutics Inc | 10/30/2024 |
9 | Monopar Therapeutics Inc Reports Q3 2024 GAAP EPS of -0.37 and Net Loss of 1.3 Million | 11/08/2024 |
10 | Monopar Therapeutics stock target lifted, buy rating on AstraZeneca deal | 11/11/2024 |
11 | Acquisition by Cittadine Andrew of 12000 shares of Monopar Therapeutics at 0.6397 subject to Rule 16b-3 | 11/14/2024 |
12 | Jones Trading raises Monopar Therapeutics target to 37 | 11/19/2024 |
| Begin Period Cash Flow | 8.2 M |
Monopar |
Monopar Therapeutics Relative Risk vs. Return Landscape
If you would invest 237.00 in Monopar Therapeutics on September 1, 2024 and sell it today you would earn a total of 2,016 from holding Monopar Therapeutics or generate 850.63% return on investment over 90 days. Monopar Therapeutics is currently generating 10.8427% in daily expected returns and assumes 77.1145% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Monopar, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Monopar Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Monopar Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Monopar Therapeutics, and traders can use it to determine the average amount a Monopar Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1406
| Best Portfolio | Best Equity | MNPR | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 77.11 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.14 actual daily | 11 89% of assets perform better |
Based on monthly moving average Monopar Therapeutics is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Monopar Therapeutics by adding it to a well-diversified portfolio.
Monopar Therapeutics Fundamentals Growth
Monopar Stock prices reflect investors' perceptions of the future prospects and financial health of Monopar Therapeutics, and Monopar Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Monopar Stock performance.
| Return On Equity | -1.02 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 111.64 M | ||||
| Shares Outstanding | 5.28 M | ||||
| Price To Earning | (35.82) X | ||||
| Price To Book | 24.04 X | ||||
| EBITDA | 429.04 K | ||||
| Net Income | (8.4 M) | ||||
| Cash And Equivalents | 16.46 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 1.76 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 7.61 X | ||||
| Book Value Per Share | 1.88 X | ||||
| Cash Flow From Operations | (7.86 M) | ||||
| Earnings Per Share | (1.98) X | ||||
| Market Capitalization | 118.91 M | ||||
| Total Asset | 7.35 M | ||||
| Retained Earnings | (60.21 M) | ||||
| Working Capital | 5.58 M | ||||
| Current Asset | 11.55 M | ||||
| Current Liabilities | 598.26 K | ||||
About Monopar Therapeutics Performance
Assessing Monopar Therapeutics' fundamental ratios provides investors with valuable insights into Monopar Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Monopar Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.14) | (1.20) | |
| Return On Capital Employed | (1.58) | (1.66) | |
| Return On Assets | (1.14) | (1.20) | |
| Return On Equity | (1.50) | (1.58) |
Things to note about Monopar Therapeutics performance evaluation
Checking the ongoing alerts about Monopar Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Monopar Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Monopar Therapeutics is way too risky over 90 days horizon | |
| Monopar Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (8.4 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Monopar Therapeutics currently holds about 16.46 M in cash with (7.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29. | |
| Monopar Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 43.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: Jones Trading raises Monopar Therapeutics target to 37 |
- Analyzing Monopar Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Monopar Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Monopar Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Monopar Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Monopar Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Monopar Therapeutics' stock. These opinions can provide insight into Monopar Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.